Reversal of early metabolic dysfunction in hypertensive rat left-ventricular myocytes by angiotensin-converting enzyme inhibition

Japanese Heart Journal

Volumn 38, Issue 4, 1997, Pages 503-514

  Watanabe, Takuya ^a   Yanagishita, Toshikuni ^a   Konno, Noburu ^a   Geshi, Eiichi ^a   Katagiri, Takashi ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibition; Calcium channel blockade; Left ventricular remodeling; Metabolic dysfunction of organelles; Single ventricular myocytes; Spontaneously hypertensive rat heart

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CALCIUM ANTAGONIST; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ORGANELLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HYPERTENSION; MALE; METABOLIC DISORDER; MITOCHONDRIAL RESPIRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SARCOLEMMA; SARCOPLASMIC RETICULUM; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0030804748     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.38.503     Document Type: Article

References (40)

1. Levy D. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-62.
2. The Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee: 1993 guidelines for the management of mild hypertension. Hypertension 1993; 22: 392-403.
3. Joint National Committee. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 1993; 153: 154-83.
4. Fleckenstein A. History of calcium antagonists. Circ Res 1983; 52: 3-16.
5. Sen S, Tarazi RC, Bumpus FM. Effects of converting enzyme inhibitor (SQ14225) on myocardial hypertrophy in spontaneously hypertensive rats. Hypertension 1980; 2: 169-76.
6. Sun Y, Ratajaska A, Weber KT. Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med 1995; 126: 95-101.
7. Clozel JP, Hefti F. Cilazapril prevents the development of cardiac hypertrophy and the decrease of coronary vascular reserve in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1988; 11: 568-752.
8. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771-9.
9. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
10. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. JAMA 1996; 275: 1507-13.
11. Watts SW, Traub O, Webb RC. Effects of ramipril on contractile oscillations in arteries from genetically hypertensive rats. Clin Exp Hypertens 1994; 16: 881-98.
12. Tytgat J. How to isolate cardiac myocytes. Cardiovasc Res 1994; 28: 280-3.
13. Burgess GM, McKinney JS, Fabiato A, Leslie BA, Putney JW. Calcium pools in saponinpermeabilized guinea pig hepatocytes. J Biol Chem 1983; 258: 15336-45.
14. Harigaya S, Schwartz A. Rate of calcium binding and uptake in normal animals and failing human cardiac muscle: membrane vesicles (relaxing system) and mitochondria. Circ Res 1969; 25: 781-94.
15. Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem 1925; 66: 375-400.
16. 2+-pumping ATPase of heart sarcolemma. J Biol Chem 1981; 256: 3263-70.
17. Matsuoka T, Yanagishita T, Kako KJ. Effects of leukocyte-derived oxidants on sarcolemmal Na, K, ATPase and calcium transport. In: Rakusan K, Biro GP, Goldstick TK, Turek Z, editors. Oxygen Transport to Tissue XI. New York: Plenum Press, 1989: 621-8.
18. Konno N, Kako KJ. Effects of hydrogen and hypochlorite on membrane potential of mitochondria in situ in rat heart cells. Can J Phvsiol Pharmacol 1991; 69: 1705-12.
19. Chance B, Williams GR. Respiratory enzymes in oxidative phosphorylation. I. Kinetics of oxygen utilization. J Biol Chem 1955; 217: 383-93.
20. Itoh S, Yanagishita T, Mukae S, Konno N, Katagiri T. Study on reperfusion injury on sarcoplasmic reticulum in acute myocardial ischemia. Jpn Circ J 1992; 56: 384-91.
21. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963; 27: 282-93.
22. 2+-dependent adenosine triphosphatase from rat cardiac sarcoplasmic reticulum. J Clin Invest 1989; 83: 1102-8.
23. Haddy FJ. Abnormalities of membrane transport in hypertension. Hypertension 1983; 5 (Suppl V): 66-72.
24. + pump activity in tail arteries of spontaneously hypertensive rats. Jpn Heart J 1979; 20 (Suppl I): 228-30.
25. 3H] ouabain binding sites in various tissues of spontaneously hypertensive rats. Eur J Pharmacol 1986; 22: 311-9.
26. Tsuruya Y, Ikeda U, Kawakami K, et al. Augmented Na, K-ATP ase gene expression in spontaneously hypertensive rat heats. Clin Exper Hypertens A 1991; 13: 1213-22.
27. +)-ATP ase from normotensive and spontaneously hypertensive rats. Arch Int Pharmacodyn 1980; 245: 139-44.
28. +-adenosine triphosphatase of spontaneously hypertensive rats. J Cardiovasc Pharmacol 1984; 6: 273-80.
29. Torii M, Ito H. Some enzyme characteristics of spontaneously hypertensive rats myocardium. Jpn Circ J 1990; 54: 688-94.
30. Bobik A, Neylon CB, Little PJ. Disturbances of vascular smooth muscle cation transport and the pathogenesis of hypertension. In: Swales JD, editor. Textbook of Hypertension. Oxford: Blackwell Scientic Publications, 1994: 175-87.
31. Tubau JF, Wikman-Coffelt J, Massie BM, et al. Diltiazem prevents hypertrophy progression, preserves systolic function, and normalizes myocardial oxygen utilization in the spontaneously hypertensive rat. Cardiovasc Res 1987; 21: 606-14.
32. Yanagishita T, Katagiri T, Iijima E, et al. Effect of diltiazem on the acute myocardial ischemic injury: comparison of the administration before and after coronary occulusion. Jpn Pharmacol Ther 1984; 12 (Suppl 7): 39-44, (in Japanese).
33. Aristizabel D, Messerli FH, Frohlich ED. Disparate structural effects on left and right ventricules by angiotension-converting enzyme inhibitors and calcium antagonists in essential hypertension. Am J Cardiol 1994; 73: 484-7.
34. Vulpis V, Roncali L, Bertossi M, et al. Left-ventricular hypertrophy in the spontaneously hypertensive rat: effect of ACE inhibitors on ultrastructural morphology. Cardiology 1994; 84: 14-24.
35. Mizuno K, Tani M, Hashimoto S, et al. Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 1992; 51: 367-74.
36. Kojima M, Shiojima I, Yamazaki T, et al. Angiotensin II receptor antagonist TCV-116 induced regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation 1994; 89: 2204-11.
37. Watanabe T, Konno N, Yanagishita N, Arata Y, Geshi E, Katagiri T. Reversal of early metabolic detriment in hypertensive rat cardiomyocytes by angiotensin-converting enzyme inhibition (abstr). J Mol Cell Cardiol 1995; 27: 514.
38. Carretero OA, Miyazaki S, Scicli AG. Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor captopril. Hypertension 1981; 3: 18-22.
39. Oliver JA, Sciacca RR. Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat. J Clin Invest 1984; 74: 1247-51.
40. Rosskopt D, Dusing R, Siffert W. Membrane sodium-proton exchange and primary hypertension. Hypertension 1993; 21: 607-17.